Azam Zahid, Shoaib Muhammad, Javed Masood, Sarwar Muhammad Adnan, Shaikh Hafeezullah, Khokhar Nasir
Prof. Zahid Azam, FCPS (Gastro); FCPS (Med); M.Sc (Clinical Research). Professor of Medicine & Gastroenterology, Gastroinstinal and Liver Practice (GILP) and Dow University of Health Sciences, Karachi, Pakistan.
Dr. Muhammad Shoaib, FCPS (Gastroenterology). Consultant Gastroenterologist, Memom Medical Institute Hospital, Karachi, Pakistan.
Pak J Med Sci. 2017 Jan-Feb;33(1):48-52. doi: 10.12669/pjms.331.12352.
The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 - 4. The objective of the study was to evaluate the interim results of efficacy and safety of regimens containing Sofosbuvir (Zoval) among Pakistani population with the rapid virologic response (RVR2/4 weeks) with HCV infections.
This is a multicenter open label prospective observational study. Patients suffering from chronic Hepatitis C infection received Sofosbuvir (Zoval) 400 mg plus ribavirin (with or without peg interferon) for 12/24 weeks. The interim results of this study were rapid virological response on week 4. Data was analyzed using SPSS version 21 for descriptive statistics.
A total of 573 patients with HCV infection were included in the study. The mean age of patients was 46.07 ± 11.41 years. Out of 573 patients 535 (93.3%) were treatment naive, 26 (4.5%) were relapser, 7 (1.2%) were non-responders and 5 (1.0%) were partial responders. A rapid virologic response was reported in 563(98.2%) of patients with HCV infection after four weeks of treatment. The treatment was generally well tolerated.
Sofosbuvir (Zoval) is effective and well tolerated in combination with ribavirin in HCV infected patients.
尿苷核苷酸类似物索磷布韦是一种丙型肝炎病毒（HCV）NS5B聚合酶的选择性抑制剂，已被批准用于治疗1 - 4型慢性HCV感染。本研究的目的是评估在巴基斯坦感染HCV且具有快速病毒学应答（2/4周）的人群中，含索磷布韦（Zoval）方案的疗效和安全性的中期结果。
这是一项多中心开放标签前瞻性观察性研究。慢性丙型肝炎感染患者接受索磷布韦（Zoval）400毫克加利巴韦林（有或无聚乙二醇干扰素）治疗12/24周。本研究的中期结果是第4周时的快速病毒学应答。使用SPSS 21版进行数据分析以进行描述性统计。
共有573例HCV感染患者纳入研究。患者的平均年龄为46.07±11.41岁。在573例患者中，535例（93.3%）为初治患者，26例（4.5%）为复发患者，7例（1.2%）为无应答者，5例（1.0%）为部分应答者。治疗4周后，563例（98.2%）HCV感染患者报告有快速病毒学应答。该治疗总体耐受性良好。
在HCV感染患者中，索磷布韦（Zoval）与利巴韦林联合使用有效且耐受性良好。
